Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome.

Author:
  • Johan Staaf
  • Markus Ringnér
  • Johan Vallon-Christersson
  • Göran B Jönsson
  • Pär-Ola Bendahl
  • Karolina Holm
  • Adalgeir Arason
  • Haukur Gunnarsson
  • Cecilia Hegardt
  • Bjarni A Agnarsson
  • Lena Luts
  • Dorthe Grabau
  • Mårten Fernö
  • Per Malmström
  • Oskar Th Johannsson
  • Niklas Loman
  • Rosa B Barkardottir
  • Åke Borg
Publishing year: 2010
Language: English
Pages: 1813-1820
Publication/Series: Journal of Clinical Oncology
Volume: 28
Issue: 11
Document type: Journal article
Publisher: American Society of Clinical Oncology

Abstract english

PURPOSE: Human epidermal growth factor receptor 2 (HER2) gene amplification or protein overexpression (HER2 positivity) defines a clinically challenging subgroup of patients with breast cancer (BC) with variable prognosis and response to therapy. We aimed to investigate the heterogeneous biologic appearance and clinical behavior of HER2-positive tumors using molecular profiling. PATIENTS AND METHODS: Hierarchical clustering of gene expression data from 58 HER2-amplified tumors of various stage, histologic grade, and estrogen receptor (ER) status was used to construct a HER2-derived prognostic predictor that was further evaluated in several large independent BC data sets. RESULTS: Unsupervised analysis identified three subtypes of HER2-positive tumors with mixed stage, histologic grade, and ER status. One subtype had a significantly worse clinical outcome. A prognostic predictor was created based on differentially expressed genes between the subtype with worse outcome and the other subtypes. The predictor was able to define patient groups with better and worse outcome in HER2-positive BC across multiple independent BC data sets and identify a sizable HER2-positive group with long disease-free survival and low mortality. Significant correlation to prognosis was also observed in basal-like, ER-negative, lymph node-positive, and high-grade tumors, irrespective of HER2 status. The predictor included genes associated with immune response, tumor invasion, and metastasis. CONCLUSION: The HER2-derived prognostic predictor provides further insight into the heterogeneous biology of HER2-positive tumors and may become useful for improved selection of patients who need additional treatment with new drugs targeting the HER2 pathway.

Keywords

  • Cancer and Oncology

Other

Published
  • CREATE Health
  • ISSN: 1527-7755
Åke Borg
Åke Borg
E-mail: ake.borg [at] med.lu.se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90